Tunlametinib plus anti-EGFR antibody for RAS-mutated GI cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (Tunlametinib and an anti-EGFR antibody) in people with advanced pancreatic or colorectal cancer that has a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced pancreatic cancer or colorectal cancer that has gotten worse after standard treatment.
- A genetic test must show your cancer has a RAS mutation.
- You must be able to take pills by mouth.
- You must be at least 18 years old and in fairly good health (able to do daily activities with little help).
- You must have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment with tunlametinib for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a KRAS mutation and has not responded to standard therapy. The goal is to see if this targeted therapy can help shrink or slow the cancer.
This trial studies a combination of two targeted drugs (Tunlametinib and Fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and has not responded to two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination (tunlametinib, AG, and cetuximab) as the first treatment for advanced pancreatic cancer. It may help people who have not had prior therapy and whose cancer has not spread to the brain or caused other serious health issues.
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
This trial tests a targeted drug (tunlametinib) for advanced thyroid cancer that has a specific genetic change called NRAS mutation. It may help people whose cancer is not responding to standard treatments like radioactive iodine.
Hear when a new Treatment for Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.